Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price target of $19.33 for the company, according to Zacks. Zacks has also assigned Aileron Therapeutics an industry rank of 107 out of 265 based on the ratings given to related companies.

A number of equities research analysts have weighed in on the stock. William Blair assumed coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They set an “outperform” rating for the company. Bank of America Corporation assumed coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They set a “buy” rating and a $19.00 target price for the company. Canaccord Genuity assumed coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They set a “buy” rating and a $19.00 target price for the company. Finally, Jefferies Group LLC assumed coverage on shares of Aileron Therapeutics in a research note on Monday, July 24th. They set a “buy” rating and a $20.00 target price for the company.

TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/25/zacks-aileron-therapeutics-inc-alrn-given-average-rating-of-strong-buy-by-brokerages.html.

In other Aileron Therapeutics news, major shareholder Cvf, Llc acquired 180,000 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was purchased at an average price of $15.00 per share, with a total value of $2,700,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Reinhard J. Ambros acquired 266,667 shares of the business’s stock in a transaction dated Wednesday, July 5th. The shares were acquired at an average cost of $15.00 per share, with a total value of $4,000,005.00. The disclosure for this purchase can be found here. In the last three months, insiders have bought 696,667 shares of company stock valued at $10,450,005.

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. bought a new stake in shares of Aileron Therapeutics during the 2nd quarter valued at $111,000. Tudor Investment Corp ET AL bought a new position in Aileron Therapeutics in the 2nd quarter worth $112,000. Citadel Advisors LLC bought a new position in Aileron Therapeutics in the 2nd quarter worth $141,000. Neuberger Berman Group LLC bought a new position in Aileron Therapeutics in the 2nd quarter worth $279,000. Finally, Laurion Capital Management LP bought a new position in Aileron Therapeutics in the 2nd quarter worth $335,000. 12.30% of the stock is owned by hedge funds and other institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.